Published in Br Med J (Clin Res Ed) on September 13, 1986
Microbial ureases: significance, regulation, and molecular characterization. Microbiol Rev (1989) 7.03
Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori. Antimicrob Agents Chemother (1991) 3.05
Campylobacter pylori and gastroduodenal disease. Clin Microbiol Rev (1990) 2.53
Prevention of nitroimidazole resistance in Campylobacter pylori by coadministration of colloidal bismuth subcitrate: clinical and in vitro studies. J Clin Pathol (1988) 2.52
Helicobacter pylori and peptic ulcers: the present position. Gut (1992) 2.27
Dyspepsia: is a trial of therapy appropriate? CMAJ (1995) 2.19
Campylobacter pylori in a sample of Finnish population: relations to morphology and functions of the gastric mucosa. Gut (1988) 1.98
Role of metronidazole resistance in therapy of Helicobacter pylori infections. Antimicrob Agents Chemother (1992) 1.92
In vitro selection of resistant Helicobacter pylori. Antimicrob Agents Chemother (1990) 1.83
Chemotactic activity of Helicobacter pylori sonicate for human polymorphonuclear leucocytes and monocytes. Gut (1992) 1.81
Transient protein losing enteropathy associated with acute gastritis and campylobacter pylori. Arch Dis Child (1987) 1.39
Guinea pig model for antibiotic transport across gastric mucosa: inhibitory tissue concentrations of clindamycin against Helicobacter pylori (Campylobacter pylori) following two separate dose regimens. Antimicrob Agents Chemother (1990) 1.35
Non-ulcer dyspepsia and short term De-Nol therapy: a placebo controlled trial with particular reference to the role of Campylobacter pylori. Gut (1988) 1.31
Evaluation of a rapid urease test to detect Campylobacter pylori infection. J Clin Microbiol (1988) 1.31
Potent inhibitory action of the gastric proton pump inhibitor lansoprazole against urease activity of Helicobacter pylori: unique action selective for H. pylori cells. Antimicrob Agents Chemother (1993) 1.28
Antibody titres to Campylobacter pylori after treatment for gastritis. BMJ (1988) 1.27
Rapid fingerprinting of Helicobacter pylori by polymerase chain reaction and restriction fragment length polymorphism analysis. J Clin Microbiol (1993) 1.26
In vitro synergistic activity between bismuth subcitrate and various antimicrobial agents against Campylobacter pyloridis (C. pylori). Antimicrob Agents Chemother (1987) 1.25
Local gastric and serum amoxicillin concentrations after different oral application forms. Antimicrob Agents Chemother (1993) 1.25
In vitro activities of new oral beta-lactams and macrolides against Campylobacter pylori. Antimicrob Agents Chemother (1989) 1.23
Treatment after failure: the problem of "non-responders". Gut (1999) 1.22
Eradication of Helicobacter mustelae from the ferret stomach: an animal model of Helicobacter (Campylobacter) pylori chemotherapy. Antimicrob Agents Chemother (1990) 1.19
Pernicious anaemia and Campylobacter like organisms; is the gastric antrum resistant to colonisation? Gut (1989) 1.17
Helicobacter pylori and gastritis in patients with peptic ulcer and non-ulcer dyspepsia: ethnic differences in Singapore. Gut (1990) 1.16
The prevalence of Campylobacter pylori gastritis among asymptomatic adults. CMAJ (1989) 1.14
Helicobacter pylori and gastric cancer: correlation with gastritis, intestinal metaplasia, and tumour histology. Gut (1992) 1.13
Gastroduodenal mucosa in uraemia: endoscopic and histological correlation and prevalence of helicobacter-like organisms. Gut (1990) 1.10
Binding and killing of bacteria by bismuth subsalicylate. Antimicrob Agents Chemother (1989) 1.08
In vitro and in vivo antibacterial activities of TAK-083, an agent for treatment of Helicobacter pylori infection. Antimicrob Agents Chemother (2001) 1.06
Patterns of colonisation of Campylobacter pylori in the oesophagus, stomach and duodenum. Gut (1989) 1.06
Effect of colloidal bismuth subcitrate on symptoms and gastric histology in non-ulcer dyspepsia. A double blind placebo controlled study. Gut (1990) 1.06
Cholesterol enhances Helicobacter pylori resistance to antibiotics and LL-37. Antimicrob Agents Chemother (2011) 1.02
Campylobacter pylori gastritis: long term results of treatment with amoxycillin. Arch Dis Child (1989) 1.01
Campylobacter associated gastritis in patients with non-ulcer dyspepsia. J Clin Pathol (1988) 1.01
Association of Helicobacter pylori with HLA-DR antigen expression in gastritis. J Clin Pathol (1992) 1.01
Comparative in vitro activities of six new fluoroquinolones and other oral antimicrobial agents against Campylobacter pylori. Antimicrob Agents Chemother (1989) 1.01
Helicobacter pylori--our knowledge is growing. Postgrad Med J (1990) 0.98
Helicobacter pylori: bridging the credibility gap. Gut (1990) 0.97
Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis. World J Gastroenterol (2008) 0.97
Retrospective study of Campylobacter-like organisms in patients undergoing partial gastrectomy. J Clin Pathol (1988) 0.95
Secretion of intravenously administered antibiotics in gastric juice: implications for management of Helicobacter pylori. J Clin Pathol (1992) 0.91
Campylobacter pylori in the upper gastrointestinal tract of patients with HIV-1 infection. J Clin Pathol (1990) 0.90
Imprint cytology--a cheap, rapid and effective method for diagnosing Helicobacter pylori. Postgrad Med J (1993) 0.89
Antimicrobial therapies for Helicobacter pylori infection in gnotobiotic piglets. Antimicrob Agents Chemother (1998) 0.87
Do patients with non-ulcer dyspepsia respond differently to Helicobacter pylori eradication treatments from those with peptic ulcer disease? A systematic review. World J Gastroenterol (2005) 0.83
Gastric penetration of amoxicillin in a human Helicobacter pylori-infected xenograft model. Antimicrob Agents Chemother (1999) 0.82
Effect of ranitidine bismuth citrate on postprandial plasma gastrin and pepsinogens. Gut (1993) 0.80
Eradication of Helicobacter pylori: therapies and clinical implications. Postgrad Med J (1992) 0.80
The effect of eradication of Helicobacter pylori upon the duodenal ulcer recurrence--a 24 month follow-up study. Korean J Intern Med (1994) 0.78
In vitro and in vivo activities of HPi1, a selective antimicrobial against Helicobacter pylori. Antimicrob Agents Chemother (2014) 0.77
Helicobacter pylori and gastrointestinal symptoms. Arch Dis Child (1994) 0.76
Helicobacter pylori: the place of the new macrolides in the eradication of the bacteria in peptic ulcer disease. Infection (1995) 0.76
Tripotassium dicitrato bismuthate on unhealed duodenal ulcers. Gut (1988) 0.75
Expression of HLA-DR antigen in different histological types of gastric polyp. J Clin Pathol (1992) 0.75
Campylobacter pyloridis: a new organism to explain an old problem? Postgrad Med J (1987) 0.75
Campylobacter pylori--a bacterial cause of peptic ulcer disease. Bull N Y Acad Med (1989) 0.75
Campylobacter enteritis: a "new" disease. Br Med J (1977) 34.77
Attempt to fulfil Koch's postulates for pyloric Campylobacter. Med J Aust (1985) 10.75
The minimum inhibitory and bactericidal concentrations of antibiotics and anti-ulcer agents against Campylobacter pyloridis. J Antimicrob Chemother (1986) 3.94
Campylobacter pyloridis in peptic ulcer disease: microbiology, pathology, and scanning electron microscopy. Gut (1985) 3.48
Rapid diagnosis of Campylobacter-associated gastritis. Lancet (1985) 3.38
Healing and recurrence of duodenal ulcer after treatment with tripotassium dicitrato bismuthate (TDB) tablets or cimetidine. Gut (1986) 1.83
Absence of therapeutic benefit from antacids or cimetidine in non-ulcer dyspepsia. N Engl J Med (1986) 1.79
[Bismuth treatment and blood bismuth levels]. Sem Hop (1977) 1.72
Histological appearances of oesophagus, antrum and duodenum and their correlation with symptoms in patients with a duodenal ulcer. Gut (1985) 1.54
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med (1993) 102.56
In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents. Antimicrob Agents Chemother (1983) 21.48
An immunoglobulin heavy chain variable region gene is generated from three segments of DNA: VH, D and JH. Cell (1980) 10.35
Two mRNAs can be produced from a single immunoglobulin mu gene by alternative RNA processing pathways. Cell (1980) 9.86
Pharmacokinetics and tissue penetration of ciprofloxacin. Antimicrob Agents Chemother (1983) 8.82
The influence of protein binding upon tissue fluid levels of six beta-lactam antibiotics. J Infect Dis (1980) 8.40
Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens (2004) 8.32
General practice fundholding. BMJ (1990) 6.43
Mechanisms of fear extinction. Mol Psychiatry (2006) 5.44
Identification of the receptor component of the IkappaBalpha-ubiquitin ligase. Nature (1998) 4.89
HR 756, a highly active cephalosporin: comparison with cefazolin and carbenicillin. Antimicrob Agents Chemother (1978) 4.74
Spiral bacteria of the gastric antrum. Lancet (1984) 4.74
Antibody diversity: somatic hypermutation of rearranged VH genes. Cell (1981) 4.65
LY127935, a novel oxa-beta-lactam: an in vitro comparison with other beta-lactam antibiotics. Antimicrob Agents Chemother (1979) 4.52
Geobacter sulfurreducens sp. nov., a hydrogen- and acetate-oxidizing dissimilatory metal-reducing microorganism. Appl Environ Microbiol (1994) 4.44
Antimicrobial resistance. Is a major threat to public health. BMJ (1998) 4.18
The pharmacokinetics and tissue penetration of ofloxacin. J Antimicrob Chemother (1984) 4.15
Functional anatomy of a common semantic system for words and pictures. Nature (1996) 4.14
Pharmacokinetics of Ro 13-9904, a broad-spectrum cephalosporin. Antimicrob Agents Chemother (1980) 4.07
Activation of the left amygdala to a cognitive representation of fear. Nat Neurosci (2001) 3.71
Activity of azlocillin and mezlocillin against gram-negative organisms: comparison with other penicillins. Antimicrob Agents Chemother (1978) 3.68
A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature (1992) 3.59
Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother (1998) 3.58
The anatomy of phonological and semantic processing in normal subjects. Brain (1992) 3.41
Extinction of fear-potentiated startle: blockade by infusion of an NMDA antagonist into the amygdala. J Neurosci (1992) 3.40
Rapid diagnosis of Campylobacter-associated gastritis. Lancet (1985) 3.38
In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob Agents Chemother (1997) 3.22
High molecular gas fractions in normal massive star-forming galaxies in the young Universe. Nature (2010) 3.18
Definition of subchromosomal intervals around the myotonic dystrophy gene region at 19q. Genomics (1989) 3.16
Association of Helicobacter pylori infection with coronary heart disease. Study shows association between H pylori infection and hypertension. BMJ (1996) 3.00
Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Diabetologia (2009) 2.98
Double dissociation between the involvement of the bed nucleus of the stria terminalis and the central nucleus of the amygdala in startle increases produced by conditioned versus unconditioned fear. J Neurosci (1997) 2.90
Mupirocin resistance. Lancet (1991) 2.88
Determinants of participation in state-of-the-art cancer prevention, early detection/screening, and treatment trials among African-Americans. Cancer Nurs (1993) 2.87
Susceptibility of clinical isolates of Campylobacter pyloridis to 11 antimicrobial agents. Antimicrob Agents Chemother (1985) 2.85
Pharmacokinetics of intravenously administered ciprofloxacin. Antimicrob Agents Chemother (1984) 2.83
Pharmacokinetics and tissue penetration of enoxacin. Antimicrob Agents Chemother (1984) 2.79
Campylobacter pylori urease: a new serological test. Lancet (1988) 2.78
A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Ann Intern Med (1991) 2.75
A primary acoustic startle circuit: lesion and stimulation studies. J Neurosci (1982) 2.73
Trends in sexual behaviour among London homosexual men 1998-2003: implications for HIV prevention and sexual health promotion. Sex Transm Infect (2004) 2.72
Exacerbation of pain by anxiety is associated with activity in a hippocampal network. J Neurosci (2001) 2.68
Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother (1999) 2.64
Local surveillance of antimicrobial resistance. Synercid Resistance Surveillance Group. Lancet (1998) 2.60
In vitro study of clavulanic acid in combination with penicillin, amoxycillin, and carbenicillin. Antimicrob Agents Chemother (1978) 2.58
Colon perforation during colonoscopy: surgical versus conservative management. Br J Surg (1991) 2.58
Fear and anxiety: animal models and human cognitive psychophysiology. J Affect Disord (2000) 2.58
Reward circuitry activation by noxious thermal stimuli. Neuron (2001) 2.56
A radiation hybrid map of the rat genome containing 5,255 markers. Nat Genet (1999) 2.54
Mouse Cmu heavy chain immunoglobulin gene segment contains three intervening sequences separating domains. Nature (1980) 2.52
Comparison of in vitro activity of GR 20263, a novel cephalosporin derivative, with activities of other beta-lactam compounds. Antimicrob Agents Chemother (1980) 2.51
Value of a centralised approach in the management of haematemesis and melaena: experience in a district general hospital. Gut (1990) 2.49
The in-vitro activity of CP 99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents. J Antimicrob Chemother (1995) 2.49
Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime. Antimicrob Agents Chemother (1981) 2.48
In vitro activity of Ro 15-8074 and Ro 19-5247, two orally administered cephalosporin metabolites. Antimicrob Agents Chemother (1986) 2.45
Comparison of the modified Stokes' method of susceptibility testing with results obtained using MIC methods and British Society of Antimicrobial Chemotherapy breakpoints. J Antimicrob Chemother (1998) 2.42
Antibodies to the surface of halothane-altered rabbit hepatocytes in patients with severe halothane-associated hepatitis. N Engl J Med (1980) 2.41
MRI in schistosomiasis of conus medullaris and lumbar spinal cord. Lancet (1993) 2.40
The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrob Agents Chemother (1992) 2.38
Mycobacterium chelonei isolation from broncho-alveolar lavage fluid and its practical implications. J Hosp Infect (1990) 2.37
A reassessment of the in-vitro activity of colistin sulphomethate sodium. J Antimicrob Chemother (1997) 2.37
Clavulanic acid and CP-45,899: a comparison of their in vitro activity in combination with penicillins. J Antimicrob Chemother (1980) 2.35
Sustaining safe sex: a longitudinal study of a sample of homosexual men. AIDS (1993) 2.35
Gene for alpha-chain of human T-cell receptor: location on chromosome 14 region involved in T-cell neoplasms. Science (1985) 2.33
Azithromycin concentrations at the sites of pulmonary infection. Eur Respir J (1990) 2.33
Long-term memory is facilitated by cAMP response element-binding protein overexpression in the amygdala. J Neurosci (2001) 2.30
Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. Arthritis Rheum (1999) 2.22
Prevalence and clinical correlates of bronchoreversibility in severe emphysema. Eur Respir J (2009) 2.18
Blocking of acquisition but not expression of conditioned fear-potentiated startle by NMDA antagonists in the amygdala. Nature (1990) 2.17
A point mutation in the human cytomegalovirus DNA polymerase gene confers resistance to ganciclovir and phosphonylmethoxyalkyl derivatives. Antimicrob Agents Chemother (1993) 2.16
The pharmacokinetics and tissue penetration of norfloxacin. J Antimicrob Chemother (1984) 2.15
Comparative pharmacokinetics and tissue penetration of sulbactam and ampicillin after concurrent intravenous administration. Antimicrob Agents Chemother (1982) 2.12
Early and late weight gain following smoking cessation in the Lung Health Study. Am J Epidemiol (1998) 2.10
In-vitro activity of sparfloxacin, a new quinolone antimicrobial agent. J Antimicrob Chemother (1990) 2.09
Role of the hippocampus, the bed nucleus of the stria terminalis, and the amygdala in the excitatory effect of corticotropin-releasing hormone on the acoustic startle reflex. J Neurosci (1997) 2.09
Extraskeletal Ewing's sarcoma. Cancer (1999) 2.08
Comparison of the in vitro activity of Bay k 4999 and piperacillin, two new antipseudomonal broad-spectrum penicillins, with other beta-lactam drugs. Antimicrob Agents Chemother (1978) 2.07
In vitro activity of Ro 23-6240, a new difluoroquinolone derivative, compared with that of other antimicrobial agents. Antimicrob Agents Chemother (1986) 2.04
Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia (2009) 2.04
Provision of vascular surgery in England in 2012. Eur J Vasc Endovasc Surg (2012) 2.02
Inflammatory pseudotumor of the alimentary tract: clinical and surgical experience. J Pediatr Surg (2001) 2.01
In-vitro activity of enoxacin (CL-919), a new quinoline derivative, compared with that of other antimicrobial agents. J Antimicrob Chemother (1984) 2.01
Thromboembolism in inflammatory bowel disease: role of platelets. Gut (1993) 2.00
Prophylactic use of cephazolin against wound sepsis after cholecystectomy. Br Med J (1977) 1.97
Reproducibility of random amplified polymorphic DNA (RAPD) analysis among laboratories. PCR Methods Appl (1993) 1.97
Clinical and laboratory investigations on ticarcillin, an anti-pseudomonal antibiotic. Chemotherapy (1974) 1.97
Evaluation of a new selective medium for Campylobacter pylori. Eur J Clin Microbiol Infect Dis (1988) 1.96
Pharmacokinetics and tissue penetration of Ro 23-6240, a new trifluoroquinolone. Antimicrob Agents Chemother (1987) 1.96
Fear-potentiated startle in humans: effects of anticipatory anxiety on the acoustic blink reflex. Psychophysiology (1991) 1.95
Commercially available fluorescein-conjugated monoclonal antibody for determining the in vitro activity of antimicrobial agents against Chlamydia trachomatis. Eur J Clin Microbiol (1987) 1.93
Rapid diagnosis of Campylobacter pyloridis gastritis. Lancet (1986) 1.92
The cortical localization of the lexicons. Positron emission tomography evidence. Brain (1992) 1.91
Spiral organisms in the gastric antrum. Lancet (1987) 1.90